Use of Chinese hamster ovary cell lines transfected with cloned human thyrotropin receptor for the measurement of thyroid-stimulating antibodies: advantages and difficulties.

Laboratoire de Génétique Moléculaire et Hormonologie, CHU de Pontchaillou, rue H. Le Guilloux, 35043, Rennes, France.
Clinica Chimica Acta (Impact Factor: 2.85). 01/2000; 291(1):67-81. DOI: 10.1016/S0009-8981(99)00198-9
Source: PubMed

ABSTRACT We compared the activities of thyroid-stimulating antibodies (TSAb) as measured with two cell lines (JP26 and JP26/26) transfected with cloned human thyrotropin (TSH) receptor and the values for TSAb measured on human thyrocytes cultures. Sera were obtained from patients with Graves' disease, before, during and after therapy with carbimazole (1-methyl-2-thio-3-carbethoxyimidazole). The activities of TSAb performed with the three assays correlated significantly. The TSAb technique using JP26/26 cells was as sensitive as the method performed on human thyrocyte cultures since positive TSAb values were found in 45 out of 47 (95.7%) newly diagnosed patients, in 100% of patients who relapsed after drug withdrawal and in none in remission. When the JP26 cell line was used, sensitivity decreased as the detection rate was only 53.2 and 55.5% before treatment and in case of relapse, respectively. The TSH receptors analysis showed a receptor density two times higher for JP26/26 than for JP26. JP26/26 cells provide similar diagnostic information on human thyrocytes in patients with Graves' disease. Moreover with these cells, the procedure for cell culture is less cumbersome and precision is better. However, rigorous culture conditions are required to maintain TSH receptor expression in transfected cells.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work, we compared the activities of TSH binding inhibitory immunoglobulin (TBII) results obtained with a new human TBII assay (h-TBII) using the human recombinant TSH receptor with thyroid stimulating antibodies (TSAbs). Sera were obtained from 90 patients with Graves' disease before and after therapy with carbimazole (1-methyl-2-thio-3-carbethoxyimidazole). Before treatment, h-TBII were detected in 89/90 patients (98.9%) whereas TSAb activity was positive in 88/90 patients (97.7%). The two parameters fell during therapy. At the end of treatment, only h-TBII levels were significantly different between patients in remission and those in relapse (Z=-2.212; P=0.0270). The relapse rate in the patients with positive antibodies at drug withdrawal was significantly increased (chi(2)=6.057; P=0.0139 for h-TBII and chi(2)=8.988; P=0.0021 for TSAb). Most of patients (76%) relapsed during the 2 years following drug withdrawal. h-TBII or TSAb values were positive in 84.6% or in 80.8% of patients at the time of relapse. There was a significant correlation between the two antibody measurement methods before treatment, at drug withdrawal and at the time of relapse. These results indicate that the new TBII assay using human TSH receptor is as sensitive as the TSAb assay. Because of its much easier performance, it may advantageously replace TSAb measurement especially for the Graves' disease diagnosis and in the prediction of short-term relapse at the end of treatment.
    Clinica Chimica Acta 03/2001; 304(1-2):39-47. · 2.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An adaptive comb filtering method, which was initially investigated by Frazier et al. [5] for the enhancement of degraded speech due to additive noise, is applied for estimating vocal noise generated at the glottis due to pathological changes of the vocal folds. In applying the method, special emphasis is placed on the accurate determination of pitch period durations. The amount of estimated vocal noise is quantified by a novel acoustic measure, normalized noise energy(NNE). Experiments with vowel samples spoken by 64 normal control subjects and 50 patients with glottic cancer have shown that the NNE is useful for the distinction between normal and pathological voice status.
    Acoustics, Speech, and Signal Processing, IEEE International Conference on ICASSP '86.; 05/1986
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperthyroidism in Gravesˈdisease is attributable to the presence of TSH-receptor antibodies : thyroid stimulating antibodies (TSAb) and TSH binding inhibiting immunoglobulins (TBII). A new assay for TBII using a recombinant human receptor is now commercially available (Dynotest TRAK human, Brahms). We have evaluated its analytical and clinical performances in the diagnostic and in the follow-up of Gravesˈdisease. We have also compared them to those obtained for porcine TRAK (TRAK assay) and for TSAb measured on cellular cultures. We studied here 154 patients with Gravesˈdisease before and after treatment with antithyroid drugs (ATD). The performances of TBII assay with human TRAK were higher than those obtained for porcine TRAK and sometimes for TSAb. Thus TBII shoud be now measured with this commercially kit. Moreover, this new assay can advantageously replace TSAb measurement in the diagnosis and in the follow-up of Gravesˈpatients treated with ATD.
    Immuno-analyse & Biologie Specialisee - IMMUNO-ANAL BIOL SPEC. 01/2002; 17(1):26-32.